Success Metrics

Clinical Success Rate
76.9%

Based on 10 completed trials

Completion Rate
77%(10/13)
Active Trials
0(0%)
Results Posted
90%(9 trials)
Terminated
3(21%)

Phase Distribution

Ph phase_3
4
29%
Ph phase_2
9
64%
Ph phase_1
1
7%

Phase Distribution

1

Early Stage

9

Mid Stage

4

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
1(7.1%)
Phase 2Efficacy & side effects
9(64.3%)
Phase 3Large-scale testing
4(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

10 of 14 finished

Non-Completion Rate

28.6%

4 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(10)
Terminated(4)

Detailed Status

Completed10
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
76.9%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (7.1%)
Phase 29 (64.3%)
Phase 34 (28.6%)

Trials by Status

terminated321%
withdrawn17%
completed1071%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT03201900Phase 3

Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)

Completed
NCT03780907Phase 2

Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With Epilepsy

Completed
NCT00592904Phase 2

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

Completed
NCT02116907Phase 1

An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male Subjects

Completed
NCT00286897Phase 3

The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Completed
NCT00154063Phase 2

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

Completed
NCT00165789Phase 2

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

Completed
NCT01172379Phase 2

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias

Completed
NCT00416195Phase 2

Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures

Completed
NCT00360412Phase 3

A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Terminated
NCT00360308Phase 3

Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Terminated
NCT00451633Phase 2

The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations

Withdrawn
NCT00427011Phase 2

A Study of E2007 In Patients With Parkinson's Disease

Terminated
NCT00849212Phase 2

An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14